Estudio abierto, multicéntrico, Fase 2 de CNTO 888 (anticuerpo monoclonal anti-CCL2) como agente único para el tratamiento de sujetos con cáncer de ovario recurrente.

Trial Profile

Estudio abierto, multicéntrico, Fase 2 de CNTO 888 (anticuerpo monoclonal anti-CCL2) como agente único para el tratamiento de sujetos con cáncer de ovario recurrente.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Apr 2012

At a glance

  • Drugs Carlumab (Primary)
  • Indications Ovarian cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Apr 2012 Additional location [United Kingdom] identified as reported by as reported by European Clinical Trials Database.
    • 28 Apr 2012 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
    • 14 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top